Meeting
2022 ASCO Annual Meeting
Immuno-multiple reaction monitoring (iMRM) for quantitation of PD-L1 and PD-1-signaling proteins in non-small cell lung carcinoma (NSCLC).
Authors
Vincent Lacasse
Lady Davis Institute & McGill University, Montreal, QC, Canada
Vincent Lacasse , Vincent Richard , Hangjun Wang , Georgia Mitsa , Olivier Poetz , Andreas I Papadakis , Mounib Elchebly , Victor Cohen , Jason S. Agulnik , Gerald Batist , Rene P. Zahedi , Christoph H. Borchers , Alan Spatz
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Immunotherapy
Track
Developmental Therapeutics—Immunotherapy
Sub Track
Tissue-Based Biomarkers
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 2627)
DOI
10.1200/JCO.2022.40.16_suppl.2627
Abstract #
2627
Poster Bd #
282
Abstract Disclosures
Similar Posters
Poster
2018 ASCO Annual Meeting
CD8 and PD-L1 determination in lung tumor tissue as prognostic biomarker and a predictive marker of anti PD-1 efficacy.
First Author: Jean-David Fumet
Poster
2018 ASCO-SITC Clinical Immuno-Oncology Symposium
The prognostic significance of PDL1 expression in locally advanced non-small-cell lung cancer (LA-NSCLC) treated with definitive intent.
First Author: Devarati Mitra
Poster
2017 ASCO Annual Meeting
Phase II clinical trial of atezolizumab (A) in advanced non-small cell lung cancer (NSCLC) patients (pts) previously treated with PD1-directed therapy.
First Author: Saveri Bhattacharya
Poster
2016 ASCO Annual Meeting
Patterns of PD-1, PD-L1 and PD-L2 expression in pediatric solid tumors.
First Author: Navin R. Pinto